ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio.
| Website | http://www.zymogenetics.com |
| Revenue | $43 million |
| Employees | 128 (0 on RocketReach) |
| Founded | 1981 |
| Fax | (206) 428-2747 |
| Industry | Manufacturing General, Drug Discovery, Manufacturing, Pharmaceuticals |
| Keywords | Protein Therapeutics, Biotechnology, Drug Development, Therapeutic Proteins, Drug Discovery, Novel Therapeutics, Pharmaceutical, Biologics, Biopharmaceutical, Protein Engineering, Clinical Trials, Pharmaceutical Research, Biotechnology Research, Pipeline Development, Biopharma, Clinical Stage, Life Sciences, Therapeutics, Medicine, Health |
| Competitors | Amgen, Genzyme Europe B.V., Biogen, Regeneron, AbbVie, Roche, Lilly India, Gilead Sciences, Novartis, Sanofi +44 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325412 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular ZymoGenetics , Inc. employee's phone or email?
ZymoGenetics , Inc. Questions
The ZymoGenetics , Inc. annual revenue was $43 million in 2026.
ZymoGenetics , Inc. is based in Seattle, Washington.
The NAICS codes for ZymoGenetics , Inc. are [325412, 32, 325, 32541, 3254].
The SIC codes for ZymoGenetics , Inc. are [28, 283].
